TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

ACE Inhibitor

Brand names: Trandolapril and Verapamil Hydrochloride

Oral

Mechanism of Action

ACE Inhibitor agent

Indications

consideration should be given to the fact that an angiotensin converting enzyme inhibitor

captopril

has caused agranulocytosis

particularly in patients with renal impairment or collagen vascular disease

and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS - Neutropenia/Agranulocytosis ).

Contraindications

• Lown-Ganong-Levine syndromes) (see WARNINGS ). 6. Patients taking flibanserin (see PRECAUTIONS - Drug Interactions ). Because of the trandolapril component
• sacubitril). Do not administer trandolapril and verapamil hydrochloride extended-release tablets within 36 hours of switching to or from sacubitril/valsartan
• a neprilysin inhibitor (see WARNINGS ).

FDA Warnings

WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue trandolapril and verapamil hydrochloride extended-release tablets as soon as possible
• Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS: Fetal Toxicity )

Known Side Effects

12 documented side effects by frequency

Shortness of Breath

1-10%

Fatigue

1-10%

Dizziness

1-10%

Diarrhea

1-10%

Weakness

1-10%

Cough

1-10%

Drug Not Working

1-10%

Nausea

1-10%

Low Blood Pressure

1-10%

High Blood Pressure

1-10%

Joint Pain

0.1-1%

Headache

0.1-1%

Community Discussions

No community discussions found for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE yet.

Compare With

8 available comparisons

Formulations

Dosage Forms

Tablet

Route

Oral